Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treat-JIA: Maintenance Versus Tapered TNF Inhibitor Monotherapy in JIA
NCT07904780Phase 4Not yet recruiting
- Sponsor
- Oslo University Hospital
- Start
- Nov 2026
- Primary completion
- Nov 2029
- Countries
- 1
01
Overview
A Phase 4 trial of adalimumab, etanercept, golimumab in juvenile idiopathic arthritis (JIA), sponsored by Oslo University Hospital. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on NCT07904780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07904780.